ArticleJournal of asthma and allergy2026
Comorbidity of Allergic Asthma and Rhinitis and High Allergen-Specific IgE are Risk Factors for Systemic Reactions to House Dust Mite Immunotherapy in Children.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To observe the adverse reactions during standardized dust mite allergen subcutaneous immunotherapy (SCIT) in children with allergic asthma (AA) and/or allergic rhinitis (AR), and to analyze the clinical characteristics and potential risk factors. Methods: This single-center retrospective cohort study included 250 children with allergic diseases who received house dust mite (HDM) SCIT treatment at our hospital from July 2022 to July 2025. The participants were divided into a systemic reactions (SRs) group and a non-SRs group. Differences in baseline clinical data and laboratory indicators between the two groups were compared, and independent risk factors for SRs were analyzed using the generalized estimating equation (GEE) method. Results: Among 250 children (9,244 injections), 114 (45.6%) experienced SRs, with an incidence of 3.47% per injection. SRs were predominantly characterized by immediate, mild grade I reactions, with only 2 cases of grade III reactions and no fatal or serious adverse events. The incidence of SRs during the maintenance period was higher than during the up-dosing period. Univariate analysis showed that the occurrence of SRs was associated with age 5-9 years, AR combined with AA, elevated total immunoglobulin E (IgE), and high Dermatophagoides pteronyssinus (Der.p) specific IgE (sIgE) levels (P < 0.05). Multivariate GEE analysis showed that AR+AA comorbidity (compared to AA alone, odds ratio [OR] = 2.219, 95% confidence interval [CI]: 1.061-4.638, Conclusion: HDM SCIT in children demonstrates a favorable safety profile, with SRs being predominantly mild and dose-dependent. The presence of AR+AA comorbidity (compared to AA alone) and a baseline Der.p.sIgE ≥ 17.5 IU/mL are key predictors of SR risk. These findings support pre-treatment risk stratification and suggest that children with these risk factors may benefit from a more individualized and monitored SCIT protocol to enhance safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.